Target intelligence / Profile preview

Constitutive photomorphogenic 1 E3 ubiquitin ligase (COP1)

Target
COP1
Molecular classification
E3 ubiquitin ligase, RING-finger protein, Enzyme
01

Overview

Constitutive photomorphogenic 1 E3 ubiquitin ligase (COP1) is a RING-finger type E3 ubiquitin ligase conserved from plants to humans. COP1 mediates the transfer of ubiquitin to specific substrate proteins, marking them for degradation by the proteasome. In plants, COP1 acts as a central repressor of light-mediated development and operates in concert with SPA proteins and as part of a CUL4-DDB1-RBX1 ligase complex[1]. In mammals (also annotated as RFWD2), COP1 regulates the stability of key transcription factors and tumor suppressors, such as p53 and c-Jun, thereby modulating cell cycle progression, apoptosis, and oncogenic signaling. While its central roles in cellular homeostasis and cancer highlight COP1 as a potential therapeutic intervention point, there are currently no approved drugs specifically targeting COP1. Pharmacological modulation of E3 ligases like COP1 remains a promising but challenging area for drug development due to concerns about specificity and broad biological effects[1][2][3].

Other names
Constitutive photomorphogenic 1COP1RFWD2 (in humans)RING finger and WD repeat domain 2
02

Mechanism of action

Protein ubiquitination and proteasomal degradation (e.g., destabilization of p53 and c-Jun); Substrate-specific degradation in multi-protein E3 complexes

03

Biological functions

Protein ubiquitinationProteasome-mediated protein degradationRegulation of light signaling (plants)Regulation of transcription factor stability (e.g., p53, c-Jun, 14-3-3 sigma)Cell cycle controlApoptosis regulationStress response
04

Disease associations

CancerNeurodevelopmental disorders (e.g., autism spectrum disorder)Other (plant developmental defects)
05

Safety considerations

Potential for on-target toxicity due to broad impact on protein turnoverDisruption of cell cycle or apoptosis, leading to possible tumorigenic risk or other cellular dysfunction if not properly controlled
06

Interacting drugs

None specifically approved or clinically established; E3 ligase inhibitors and PROTACs may target E3 ligases in cancer research, but no direct clinical drugs known to selectively target COP1 as of now
07

Biomarkers

No widely established biomarkers for patient selection or monitoring efficacy specific to COP1, though p53 or c-Jun stability or degradation could serve as mechanistic readouts in research settings

Beyond the preview

Go deeper on Constitutive photomorphogenic 1 E3 ubiquitin ligase (COP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Constitutive photomorphogenic 1 E3 ubiquitin ligase (COP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call